Understand the source comparison
VIP for CIRS Treatment: Comparison
Cholestyramine / Welchol Binders Bile acid sequestrants bind mycotoxins in gut, preventing enterohepatic recirculation and promoting fecal excretion Step 1–2: initiated after mold exposure removed Mycotoxin clearance, indirect reduction in C4a and inflammatory
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cholestyramine / Welchol Binders
- Bile acid sequestrants bind mycotoxins in gut, preventing enterohepatic recirculation and promoting fecal excretion
- Step 1–2: initiated after mold exposure removed
- Mycotoxin clearance, indirect reduction in C4a and inflammatory cytokines
- 3–6 months, sometimes longer
- Foundational intervention. Clears biotoxins but does not reset immune dysregulation
- BEG Nasal Spray (Bactroban-EDTA-Gentamicin)
- Eradicates MARCoNS (antibiotic-resistant staph) colonizing nasal passages and producing exotoxins A and B that worsen inflammation
- Step 3–4: after binders reduce systemic toxin load
- MARCoNS eradication, MSH normalization, indirect TGF-beta-1 reduction
- 4 weeks (one bottle, twice daily)
- Necessary if MARCoNS present. Skipping this step prevents VIP success
- Losartan (ARB antihypertensive)
- Angiotensin receptor blocker reduces TGF-beta-1 signaling, suppressing fibrotic and autoimmune-like pathways
- Step 5–7: after MARCoNS cleared, before VIP
- TGF-beta-1 reduction (target <2,380 pg/mL)
- 3–6 months
- Effective TGF-beta-1 reducer, often required to meet VIP eligibility criteria
- VIP Nasal Spray
- VPAC2 receptor agonist shifts T-cell differentiation to Tregs, stabilizes mast cells, suppresses cytokine production (TGF-beta-1, MMP-9), restores immune tolerance
- Step 11: only after all prior steps normalize inflammatory markers
- C4a, TGF-beta-1, MMP-9, regulatory T-cell expansion, symptom resolution
- 4–6 months, 50mcg four times daily
- Final recalibration step. High success rate when sequencing is followed, fails when initiated prematurely
- VIP for CIRS treatment is not an alternative to binders or environmental remediation. It is the immune reset that follows after those interventions plateau. The comparison above demonstrates why sequencing matters: binders clear toxins, MARCoNS eradication removes inflammatory triggers, Losartan reduces fibrotic signaling, and VIP recalibrates the immune system after those foundations are set. Skipping earlier steps and jumping to VIP is biochemically illogical. The peptide modulates an immune system that must first be relieved of its inflammatory drivers.